Liver Failure Clinical Trials

⁃ A. Chronic liver failure (CLF) group:

⁃ The progressive liver function decline or decompensation after liver cirrhosis:

• Body weight\>40kg;

• Aged between 18 to 65 years old;

• Serum Total bilirubin was higher than the normal range and lower than 10 times the upper limit of normal value (ULN);

• With or without significantly decreased serum albumin value, lower than 35;

• With or without significantly decreased platelet (PLT) value, prothrombin activity (PTA)≤40% (or international normalized ratio (INR)≥1.5), other reasons excluded;

• With or without refractory ascites or portal hypertension;

• With or without a stage I or II hepatic encephalopathy;

• No obvious improvement after more than 3 days' regular clinical treatments.

⁃ OR B. Acute-on-chronic liver failure (ACLF) group:

⁃ With known or unknown basic liver diseases, subjects undergoing acute liver failure syndrome (clinical manifestations indicated as an early stage liver failure).

• Body weight\>40kg;

• Aged between 18 to 65 years old;

• With obvious fatigue, accompanied by other gastrointestinal symptoms such as anorexia, vomiting, and abdominal distension;

• Complicated with ascites and/or hepatic encephalopathy within 4 weeks after being diagnosed;

• Progressive aggravation of jaundice, total serum bilirubin≥85umol/L；

• Coagulation disorders, INR\>1.5 or PTA\<40%;

• No obvious improvement after more than 3 days' regular clinical treatments.